PBLA Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 15:27):

Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, focuses on developing disruptive therapeutics for the treatment of patients with cancer...

Stats
Today's Volume	48 233.00
Average Volume	470 665
Market Cap	1.99M
EPS	$0 ( 2024-03-26 )
Next earnings date	( $-1.230 ) 2024-05-02
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0.0300 (7.32%)

Insider Trading

Date	Person	Action	Amount	type
2023-11-08	Goldman Sachs Group Inc	Sell	72 874	Common Stock
2023-11-07	Goldman Sachs Group Inc	Buy	0	Common Stock
2023-09-12	Jacob Jeffrey E.	Sell	275	Common Stock
2023-03-27	Simpson Jennifer K.	Buy	99 383	Stock Option (right to buy)
2023-03-27	Horvath Susan	Buy	34 369	Stock Option (right to buy)

INSIDER POWER
60.80
Last 76 transactions
Buy: 2 117 070 \| Sell: 358 529

Panbela Therapeutics, Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Panbela Therapeutics, Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-25.65M (0.00 %)
EPS:	$-232 430

FY	2023
Revenue:	$0
Gross Profit:	$-25.65M (0.00 %)
EPS:	$-232 430

FY	2022
Revenue:	$0
Gross Profit:	$-35.73M (0.00 %)
EPS:	$-40 749

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-34.62

Financial Reports:

No articles found.

Panbela Therapeutics,

Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, focuses on developing disruptive therapeutics for the treatment of patients with cancer. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer, as well as neoadjuvant pancreatic cancer, colorectal cancer, ovarian cancer, and other agents in other cancer indications. Its lead product candidate is SBP-101, which is in Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.

Realtime updates for Panbela Therapeutics, [PBLA]

Upcoming Earnings Alert